EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! - Älteste Beiträge zuerst (Seite 1160)

[lson3]

Ich glaube dass 10 min täglich swieso zu wenig sind um sich um sein Portfolio zu kümmern und willst Du damit sagen dass Du die 3 Sekunden nicht hast auf kopieren und einfügen zu klicken.
Ich jedenfalls werde weiter so posten wie bisher. Es muss ja niemand lesen und jeder kann sich die Meldungen selber suchen das dauert dann länger als 10 min.

mfg

[wohinistmeinGeld]

Antwort auf Beitrag Nr.: 50.509.227 von lson3 am 28.08.15 12:16:25

na das möchte ich aber mal sehen wie einer das in 3 sek im Handy schafft

[wuenschmirwas]

Psivida liefert am 9. September nach Handelsschluss die Zahlen für das 4. Quartal 2015.

[wuenschmirwas]

Die Werbetrommel wird weiter gedreht.
http://investors.psivida.com/releasedetail.cfm?ReleaseID=930…

[binda]

“Our $28.5 million in cash at the end of fiscal year 2015 marks our highest year-end liquidity. It should give us the capital resources to continue our planned product development programs, including our two Medidur trials, into early 2017, even without any potential future payments arising from ILUVIEN,” said Dr. Ashton.

Results for the Fourth Quarter and FY 2015. Revenues for the quarter ended June 30, 2015 totaled $409,000 compared to $292,000 for the prior year’s fourth quarter. The increase was primarily due to higher Retisert royalties.
Operating expenses for the three months ended June 30, 2015 totaled $5.6 million compared to $4.3 million a year earlier. The increase was primarily attributable to higher CRO costs for the Medidur clinical development program and higher professional fees.

Net loss for the quarter ended June 30, 2015 was $5.1 million, or $0.17 per share, compared to a net loss of $4.0 million, or $0.14 per share, for the prior year quarter.



Revenues for the year ended June 30, 2015 totaled $26.6 million compared to $3.5 million for the year ended June 30, 2014. The increase reflected the $25.0 million milestone for FDA approval of ILUVIEN recorded in the fiscal 2015 first quarter, partially offset by an approximate $1.8 million reduction in revenues from funded technology evaluation agreements.

Operating expenses for the year ended June 30, 2015 totaled $20.1 million compared to $17.0 million for the same period of the prior year, with the $3.1 million net increase primarily due to increased CRO costs for the Medidur clinical development program as well as increased professional fees and stock-based compensation.

Income tax expense totaled $96,000 for the year ended June 30, 2015 compared to an income tax benefit of $130,000 for the year ended June 30, 2014. Fiscal 2015 included $263,000 of federal alternative minimum tax expense based on U.S. taxable income for calendar year 2014, which was primarily attributable to the $25.0 million ILUVIEN FDA-approval milestone. Refundable foreign research and development tax credits totaled $167,000 in fiscal 2015 compared to $130,000 in fiscal 2014.

Net income for the year ended June 30, 2015 totaled $6.3 million, or $0.21 per diluted share, compared to a net loss of $13.4 million, or $0.49 per share, for the year ended June 30, 2014.
At June 30, 2015, cash, cash equivalents and marketable securities totaled $28.5 million.


http://www.sec.gov/Archives/edgar/data/1314102/0001193125153…

[binda]

Today’s Conference Call Reminder
pSivida Corp. will host a live webcast and conference call today, September 9, 2015, at 4:30pm ET. The conference call may be accessed by dialing [phone] from the U.S. and Canada, or [phone] from international locations. The conference can also be accessed on the pSivida Corp. website at www.psivida.com. A replay of the call will be available approximately two hours following the end of the call through September 16, 2015. The replay may be accessed by dialing [phone] within the U.S. and Canada or [phone] from international locations, Conference ID number 27613566.

[binda]

[binda]

Webcast jetzt abrufbar

Q4 2015 P Sivida Corp Earnings Conference call
09 Sep, 2015 Length: 01: 05:25

http://seekingalpha.com/article/3497626-psivida-psdv-q4-2015…

[binda]

company update

http://www.asx.com.au/asxpdf/20150910/pdf/4316y4fgdrydgn.pdf

[wonner]

Antwort auf Beitrag Nr.: 50.592.893 von binda am 10.09.15 02:57:47

Was zum lesen!!!


http://finance.yahoo.com/news/edited-transcript-psdv-earning…" target="_blank" rel="nofollow ugc noopener">[/http://finance.yahoo.com/news/edited-transcript-psdv-earning…